Resources


Advanced



 Quick Order
  This area of the site
   requires the
  Acrobat Reader
  and the ability to
  view zipped files.
  Click below to
  download the
   necessary
   software.
  The StuffIt
   software can be
   used for either
   Windows or
   Macintosh.


Download the Adobe Acrobat reader

Download the StuffIt Expander

Download WinZip

 
 
Meeting Highlights
HOPE-2 trial
March 16, 2006


Download this Section   -   PowerPoint
Click any slide below for accompanying Teaching Points
1
  Slide: 1 - HOPE-2</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

HOPE-2
 
 
2
  Slide: 2 - HOPE-2: Rationale</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

HOPE-2: Rationale
 
 
3
  Slide: 3 - HOPE-2: Study design</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

HOPE-2: Study design
 
 
4
  Slide: 4 - HOPE-2: Baseline characteristics</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

HOPE-2: Baseline characteristics
 
 
5
  Slide: 5 - HOPE-2: Baseline prevalence of CV risk factors</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

HOPE-2: Baseline prevalence of CV risk factors
 
 
6
  Slide: 6 - HOPE-2: Baseline prevalence of CVD</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

HOPE-2: Baseline prevalence of CVD
 
 
7
  Slide: 7 - HOPE-2: Baseline medication use</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

HOPE-2: Baseline medication use
 
 
8
  Slide: 8 - HOPE-2: Change in plasma homocysteine over time</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

HOPE-2: Change in plasma homocysteine over time
 
 
9
  Slide: 9 - HOPE-2: Primary outcome shows no benefit of vitamin supplementation</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

HOPE-2: Primary outcome shows no benefit of vitamin supplementation
 
 
10
  Slide: 10 - HOPE-2: Primary outcome and components</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

HOPE-2: Primary outcome and components
 
 
11
  Slide: 11 - HOPE-2: Secondary outcome and components</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

HOPE-2: Secondary outcome and components
 
 
12
  Slide: 12 - HOPE-2: Summary</title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div></title><style>.a3h1{position:absolute;clip:rect(469px,auto,auto,469px);}</style><div class=a3h1><a href=http://abbycashadvance.com >cash advance</a></div>

HOPE-2: Summary
 
 

Home | Literature Update | Journal Link | Resources | Meeting Highlights | Members | About VBWG | Web Links